Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

BMI appears to be important in predicting anti-TNF efficacy in Crohn’s

This month's issue of the European Journal of Gastroenterology & Hepatology investigates whether weight-adjusted anti-tumor necrosis factor treatment favours obese patients with Crohn’s disease.

News image

Adalimumab is a subcutaneous anti-tumor necrosis factor (anti-TNF) agent, effective in inducing and maintaining remission in Crohn’s disease.

Unlike infliximab, adalimumab dosing is not weight adjusted and dose frequency is based on clinical response.

Dr Bhalme and colleagues determined whether obesity is a risk factor for early loss of response to anti-TNF treatment, and whether weight-adjusted anti-TNF treatment is favorable.

A hospital database of Crohn's disease patients receiving anti-tumor necrosis factor treatment was analyzed retrospectively.

The team of doctors assessed the relationship between time to loss of response and BMI by Kaplan–Meier survival curves and a Cox proportional hazards model.

Of the 54 patients, the team observed a significantly shorter time to dose escalation in the BMI of at least 30.

BMI appears to be important in predicting adalimumab efficacy in Crohn’s
European Journal of Gastroenterology & Hepatology

The researchers noed that the Cox proportional hazards model showed that an increased hazard of loss of response to Adalimumab is related to increases in BMI.

Of the 76 patients, the researchers showed that the differences in survival curves were not significant for the BMI groups. .

Dr Bhalme's team concluded, "BMI appears to be important in predicting adalimumab efficacy in Crohn’s disease."

"Infliximab appears to overcome this reduction of efficacy in obese patients."

"A prospective study evaluating the effect of weight on anti-tumor necrosis factor drug response and serum drug levels is warranted."

European Journal of Gastroenterology & Hepatology:2013 25(5) :543-549
30 April 2013

Go to top of page Email this page Email this page to a colleague

 30 June 2015

Advanced search
 30 June 2015 
NSAIDs and hearburn symptoms
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 29 June 2015 
Rescue therapy in ulcerative colitis
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Fecal microbiota in pediatric IBD
 24 June 2015 
Environmental risk in IBD
 24 June 2015 
Fatigue scales for IBD
 24 June 2015 
Mucosal healing tests in ulcerative colitis
 23 June 2015 
Marker associated with endoscopic lesion in Crohn's
 23 June 2015 
Body composition in children with IBD
 23 June 2015 
Medical vs nurse endoscopists
 22 June 2015 
Gene polymorphism associated with increased liver enzymes
 22 June 2015 
Treatment of uncomplicated acute appendicitis
 22 June 2015 
Solid organ cancers after liver transplant
 19 June 2015 
Causes of death in HBV
 19 June 2015 
Lifetime benefits of increased adenoma detection rates
 19 June 2015 
Acid-suppressive therapy before anti-reflux surgery
 18 June 2015 
Endoscopic activity in symptomatic IBD patients
 18 June 2015 
Regimens for H. pylori eradication
 18 June 2015 
Risk for dyspepsia
 17 June 2015 
Non-invasive markers of advanced liver fibrosis
 17 June 2015 
Patients’ and clinicians’ perception of pouch dysfunction
 17 June 2015 
NAFLD risk in celiac disease
 16 June 2015 
Esophageal food bolus impaction
 16 June 2015 
Evaluating lymph node metastasis for rectal cancer
 16 June 2015 
Risk score for hepatocellular carcinoma screening
 15 June 2015 
Low-cost colonoscopy training
 15 June 2015 
Determining dysbiosis in IBS or IBD
 15 June 2015 
Light alcohol consumption and NAFLD
 12 June 2015 
Smoking and disease course in IBD
 12 June 2015 
Hep D in a Hep B endemic area
 12 June 2015 
Patient-orientated internet information in ulcerative colitis
 11 June 2015 
Physical inactivity and NAFLD
 11 June 2015 
Esophageal stricture after endoscopic resection
 11 June 2015 
Guideline based screening strategies for hepatitis
 10 June 2015 
Cost-effectiveness of HCV treatment in liver disease
 10 June 2015 
Abdominoperineal excision for low rectal cancer
 10 June 2015 
Pediatric chronic Hep C
 09 June 2015 
Bile acid malabsorption in IBS
 09 June 2015 
Racial differences in celiac disease
 09 June 2015 
Conversion from laparoscopic to open colorectal cancer resection
 08 June 2015 
Short sleep duration and NAFLD
 08 June 2015 
Heritability in inflammatory bowel disease
 08 June 2015 
Eosinophilic esophagitis
 05 June 2015 
In-hospital mortality in patients with lower GI bleeding
 05 June 2015 
Scoring system for microscopic colitis
 05 June 2015 
H. pylori and myocardial infarction
 04 June 2015 
Mucosal healing in celiac disease and pregnancy
 04 June 2015 
Gastrointestinal microbiomes in Crohn's
 04 June 2015 
Dyspepsia in the community:
 03 June 2015 
Predicting disease activity in IBD
 03 June 2015 
Outcomes with discontinuation of therapy in Crohn's
 03 June 2015 
Biopsies in eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us